FDA Drug Recalls

Recalls / Class II

Class IID-0164-2020

Product

AVKARE Ranitidine Hydrochloride Capsules 150 mg 500 Capsules Rx Only NDC 42291-735-50 UPC 342291735507 Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Affected lot / code info
Lot 17708 Exp.11/30/2019 Lot 18459 Exp.03/31/2020 Lot 19033 Exp.07/31/2020 Lot 19032 Exp.07/31/2020 Lot 19031 Exp.06/30/2020 Lot 20204 Exp.09/30/2020 Lot 20205 Exp.09/30/2020 Lot 20663 Exp.10/31/2020 Lot 20664 Exp.11/30/2020 Lot 20665 Exp.11/30/2020 Lot 20666 Exp.11/30/2020 Lot 21039 Exp.12/31/2020 Lot 21920 Exp.04/30/2021

Why it was recalled

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Recalling firm

Firm
AVKARE Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
615 N 1st St, Pulaski, Tennessee 38478-2403

Distribution

Quantity
7293 bottles
Distribution pattern
CO, MO

Timeline

Recall initiated
2019-10-17
FDA classified
2019-10-28
Posted by FDA
2019-11-06
Terminated
2020-10-21
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0164-2020. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: drug · FDA Drug Recalls